RocketTickers

NuCana Announces FDA Clearance to Commence Phase III Study of Ac

Long
NASDAQ:NCNA   NuCana plc
NCNA: NuCana plc
2019-10-25 07:00:05
NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer